Please login to the form below

Not currently logged in
Email:
Password:

AMNOG – One Year On...

A review of the impact of new pricing and reimbursement arrangements in Germany

Once the first country in Europe to get innovative products thanks to its favourable pricing structure, Germany was a popular launch destination. But the introduction of AMNOG and the G-BA test has left many wondering if they would not be better off avoiding the country altogether Justus Dehnen, Head of Pricing & Reimbursement, IMS Consulting Group and Olaf Zweig, Principal, Booz & Co review the first year of the new arrangements in detail and provide their insights on the likely impact on pharma companies.


The expert panel includes

  • Justus Dehnen, Pricing and Market Access Leader, Germany
  • Olaf Zweig, Principal, Global Health Practice, Berlin

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Globe
Rare diseases: meeting the challenge
Problems with regulating orphan drugs...
Digital storytelling means building the story around data
The value of digital storytelling in pharma lies in its ability to convert facts and figures into compelling content for patients and HCPs....
Pharma and free medicines: a different perspective
Pfizer have recently announced that they will provide the breast cancer drug, palbociclib, free of charge to patients....

Infographics